尊龙凯时人生就是搏·(中国区)官方网站

VOLUNTARY ANNOUNCEMENT - "RECOMBINANT HUMAN COAGULATION FACTOR VIIA N01 FOR INJECTION" APPROVED FOR MARKETING

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2025

VOLUNTARY ANNOUNCEMENT - INDICATION OF ANLOTINIB HYDROCHLORIDE CAPSULES IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA APPROVED FOR MARKETING

VOLUNTARY ANNOUNCEMENT - NEW INDICATION OF LM-108 ("CCR8 MONOCLONAL ANTIBODY") INCLUDED IN BREAKTHROUGH THERAPY DESIGNATION PROCESS

VOLUNTARY ANNOUNCEMENT - PRECLINICAL AND CLINICAL DATA ON ROVADICITINIB PRESENTED AT EHA 2025

VOLUNTARY ANNOUNCEMENT - NEW INDICATION OF TDI01 SUSPENSION (“ROCK2 INHIBITOR”) INCLUDED IN BREAKTHROUGH THERAPY DESIGNATION PROCESS BY CDE

VOLUNTARY ANNOUNCEMENT - THE LATEST PROGRESS OF INNOVATION-DRIVEN DEVELOPMENT OF THE GROUP

POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 10 JUNE 2025